Alpha-lipoic Acid: An Antioxidant with Anti-Aging Properties for Disease Therapy

Current Medicinal Chemistry, Год журнала: 2024, Номер 32(1), С. 23 - 54

Опубликована: Апрель 22, 2024

The anti-aging effects of alpha-lipoic acid (αLA), a natural antioxidant synthesized in human tissues, have attracted growing interest recent years. αLA is short- -chain sulfur-containing fatty occurring the mitochondria all kinds eukaryotic cells. Both oxidized disulfide and its reduced form (dihydrolipoic acid, DHLA) exhibit prominent function. amount inside body gradually decreases with age resulting various health disorders. Its lack can be compensated by supplying from external sources such as dietary supplements or medicinal dosage forms. primary objectives this study were analysis updated information on latest two-decade research regarding use an perspective. was collected PubMed, Wiley Online Library, Scopus, ScienceDirect, SpringerLink, Google Scholar, clinicaltrials.gov. Numerous silico, vitro, vivo, clinical studies revealed that shows protective role biological systems direct indirect reactive oxygen/nitrogen species quenching. demonstrated beneficial properties prevention treatment many age-related disorders neurodegeneration, metabolic disorders, different cancers, nephropathy, infertility, skin senescence. preventive case Alzheimer's Parkinson's diseases are particular interest. Further mechanistic highly recommended to evaluate wide spectrum therapeutic potential could optimize intake for alleviation related aging.

Язык: Английский

---

Expert opinion on screening, diagnosis and management of diabetic peripheral neuropathy: a multidisciplinary approach

Frontiers in Endocrinology, Год журнала: 2024, Номер 15

Опубликована: Июнь 17, 2024

The proposed expert opinion aimed to address the current knowledge on conceptual, clinical, and therapeutic aspects of diabetic peripheral neuropathy (DPN) provide a guidance document assist clinicians for best practice in DPN care. participating experts consider suspicion disease by as key factor early recognition diagnosis, emphasizing an improved awareness first-admission or referring physicians. “screening diagnostic” algorithm involves consideration patient with prediabetes diabetes who presents neuropathic symptoms and/or signs presence risk factors, careful laboratory testing rule out other causes distal symmetric referral detailed neurological work-up confirmative test either small large nerve fiber dysfunction atypical cases. Although, first-line interventions are currently represented optimized glycemic control (mainly type 1 diabetes) multifactorial intervention 2 diabetes), there is need individualized pathogenesis-directed treatment approaches DPN. Alpha-lipoic acid (ALA) seems be important agent, given that it direct indirect antioxidant works strategy targeted directly against reactive oxygen species indirectly favor endogenous capacity improving conditions. There still gap existing research field, necessitating well-designed, robust, multicenter clinical trials sensitive endpoints standardized protocols facilitate diagnosis via simple effective track progression response. Identification biomarkers/predictors would allow approach from potentially disease-modifying perspective may opportunities novel treatments efficacious stages DPN, modify natural course disease. This expected increase among physicians about them timely translating this information into their management patients

Язык: Английский

---

Validation of the Neuropathy Impairment Score (NIS) for use in Russian-speaking patients with chronic inflammatory demyelinating polyneuropathy

Neuromuscular Diseases, Год журнала: 2025, Номер 14(4), С. 29 - 39

Опубликована: Янв. 9, 2025

Background . A clinical application of scales and questionnaires is essential for the objective evaluation treatment response, disease course, quality life disability level in patients with chronic inflammatory demyelinating polyneuropathy (CIDP). Neuropathy Impairment Score (NIS) has become widespread epidemiological studies various polyneuropathies, including CIDP. However, its Russia limited by absence validated version Russian-speaking patients. Aim. To develop Russian NIS Materials methods. The study involved 50 CIDP (25 multifocal variant (Lewis–Sumner syndrome) 25 typical CIDP). validation process included two stages: translation linguocultural ratification scale according to standard protocol an assessment psychometric properties, such as reliability, validity sensitivity. Results. developed demonstrated high sensitivity validity. Conclusion. can be recommended research practice.

Язык: Английский

---

A narrative literature review about alpha‐lipoic acid role in dry eye and ocular surface disease

Acta Ophthalmologica, Год журнала: 2025, Номер unknown

Опубликована: Апрель 10, 2025

Abstract Ocular surface diseases (OSD) include various conditions that affect the eye's surface, causing discomfort and pain. One such condition, dry eye disease (DED), is a multifactorial disorder significantly impacts patients' quality of life, with prevalence rates ranging from 5% to 50% higher incidence in women. DED involves tear film instability, inflammation neurosensory abnormalities, making its management challenging due diverse underlying mechanisms. Conventional treatments typically focus on symptom relief, but new approaches targeting disease's pathogenesis are emerging. Alpha‐lipoic acid (ALA) gaining attention for potential treating OSD DED. ALA acts as potent antioxidant, neutralizing reactive oxygen species. It protects cell membranes by interacting vitamin C glutathione, potentially recycling E. Its antioxidative properties particularly relevant meibomian gland dysfunction, condition implicated By scavenging free radicals modulating redox status glands, can reduce oxidative damage, preserve glandular function decrease inflammation. In diabetic patients DED, administration has been found improve parameters, corneal defects, enhance antioxidant prevent retinopathy keratopathy. therapeutic effects especially polyneuropathy other neuropathies, primarily anti‐inflammatory metal‐chelating properties. summary, holds promise agent could be promising treatment option keratopathy, although further research needed confirm efficacy.

Язык: Английский

---

α -Lipoic acid alleviates Parkinson’s disease by suppressing S100A9-mediated pyroptosis

International Immunopharmacology, Год журнала: 2025, Номер 155, С. 114539 - 114539

Опубликована: Апрель 14, 2025

Язык: Английский

---

Diabetic neuropathy: cutting-edge research and future directions

Signal Transduction and Targeted Therapy, Год журнала: 2025, Номер 10(1)

Опубликована: Апрель 24, 2025

Abstract Diabetic neuropathy (DN) is a prevalent and debilitating complication of diabetes mellitus, significantly impacting patient quality life contributing to morbidity mortality. Affecting approximately 50% patients with diabetes, DN predominantly characterized by distal symmetric polyneuropathy, leading sensory loss, pain, motor dysfunction, often resulting in diabetic foot ulcers lower-limb amputations. The pathogenesis multifaceted, involving hyperglycemia, dyslipidemia, oxidative stress, mitochondrial inflammation, which collectively damage peripheral nerves. Despite extensive research, disease-modifying treatments remain elusive, current management primarily focusing on symptom control. This review explores the complex mechanisms underlying highlights recent advances diagnostic therapeutic strategies. Emerging insights into molecular cellular pathways have unveiled potential targets for intervention, including neuroprotective agents, gene stem cell therapies, innovative pharmacological approaches. Additionally, novel tools, such as corneal confocal microscopy biomarker-based tests, improved early detection intervention. Lifestyle modifications multidisciplinary care strategies can enhance outcomes. While significant progress has been made, further research required develop therapies that effectively halt or reverse disease progression, ultimately improving lives individuals DN. provides comprehensive overview understanding future directions management.

Язык: Английский

---

Advances in α-Lipoic Acid for Disease Prevention: Mechanisms and Therapeutic Insights

Molecules, Год журнала: 2025, Номер 30(9), С. 1972 - 1972

Опубликована: Апрель 29, 2025

α-Lipoic acid (ALA) is a naturally occurring compound with diverse biological functions, widely distributed in animal and plant tissues. It has attracted considerable attention due to its versatile therapeutic potential. However, despite these promising prospects, the clinical application of ALA remains limited by low bioavailability chemical instability an incomplete understanding multifaceted mechanisms across various diseases. This review provides comprehensive overview biochemical properties ALA, including direct free-radical-scavenging activity, regeneration endogenous antioxidants, chelation metal ions, modulation inflammatory responses. We also highlight current evidence regarding ALA’s roles efficacy major diseases, such as neurodegenerative disorders, lung cardiovascular diabetes. Furthermore, recent advancements innovative strategies ALA-based derivatives drug-delivery systems are summarized, emphasizing their potential address complex diseases necessity for further translational studies. aims provide theoretical foundation rational design therapies, thereby supporting future applications optimization strategies.

Язык: Английский

---

Modern view on the use of alpha lipoic acid in neurological practice

Meditsinskiy sovet = Medical Council, Год журнала: 2024, Номер 5, С. 70 - 81

Опубликована: Май 10, 2024

Alpha lipoic acid (ALA) is an essential cofactor for mitochondrial enzymes, a powerful antioxidant, and important component of many metabolic processes. Most research on ALA has focused specifically its antioxidant properties. A number conditions – aging, atherosclerosis, liver cirrhosis, diabetes mellitus, various types polyneuropathy, psoriasis others can significantly reduce the level in body. The article analyzes modern literature (107 sources, including 17 systematic reviews meta-analyses). Traditionally, used complex therapy patients suffering from diabetic alcoholic polyneuropathy. However, analysis studies conducted around world not limited to these two nosological forms. use as adjuvant diseases justified, confirmed by clinical studies, meta-analyses. All assessed only effectiveness ALC, but also safety incidence adverse events showed that ALC high profile. pronounced effect, ability chelate toxic metals, increase intracellular glutathione levels, blood glucose overcome insulin resistance, participate metabolism, stimulate production cAMP, normalize lipid profile, inflammatory markers, etc. Based Because positive effect using treatment symptoms nosologies, list indications requires revision, expansion addition.

Язык: Английский

---

CLINICAL-EXPERIMENTAL JUSTIFICATION OF PATHOGENETIC TREATMENT OF DIABETIC DAMAGE OF THE PERIPHERAL NERVOUS SYSTEM

Medical Science of Ukraine (MSU), Год журнала: 2024, Номер 20(2), С. 79 - 89

Опубликована: Июнь 30, 2024

Background. Diabetes mellitus is a chronic endocrinological disease that, in addition to the somatic sphere, affects all departments and levels of nervous system. At same time, its prevalence increasing every year. Most often, neurological manifestations concern peripheral system form sensory-motor polyneuropathies. Aim: To clinically experimentally study effectiveness complex scheme prevention treatment diabetic polyneuropathy, which composed taking into account pathogenetic mechanisms studied pathology. find out clinical features course electrophysiological patterns. Under experimental conditions, dynamics changes indicators sensitivity (nociception) motor function nerves case nerve damage. Materials methods. In work, streptozotocin-induced polyneuropathy was reproduced rats experiment. The formation latter confirmed by morphological sciatic tail with determination edema degeneration Schwann cells, as well segmental demyelination spasm precapillary arterioles. Nicergoline, alpha-lipoic acid, group B vitamins, NG-nitro-L-arginine were used for therapeutic or preventive purposes groups animals. speed conduction excitation along studied. addition, "hot plate" test used. part 43 patients examined. examination; assessed severity polyneuropathies according scale neuropathy symptoms, stimulation electroneuromyography.The divided groups: first received developed complex, second conventional treatment. Results. obtained data indicate feasibility using direct (NG-nitro-L-arginine) indirect (nicergoline - "Sermion" LC "Alpha-lipon") inhibitors nitric oxide synthesis, vitamin preparations "Neovitam", their reparative antioxidant properties, clinic therapeutic, possibly purpose. positive effects DPP are associated development effects, restoration myelin sheath nerves, since contributes polyneuropathy. Conclusion. Patients who achieved probable clinical, neurophysiological improvement. On basis research, this kind improvement due myelin, blood circulation, have been proven.

Язык: Английский

---

Neuroprotection with Bioactive Compounds

Nutrients, Год журнала: 2023, Номер 15(21), С. 4612 - 4612

Опубликована: Окт. 30, 2023

Bioactive compounds are found in foods small quantities and represent extra nutritional constituents known to exert beneficial effects on health beyond their value [...]

Язык: Английский

---